Shi Mengna, Zhang Min-Jie, Yu Yang, Ou Rongying, Wang Yiyan, Li Huitao, Ge Ren-Shan
Department of Anesthesiology and Perioperative Medicine, the Second Affiliated Hospital and Yuying Children's Hospital; Key Laboratory of Pediatric Anesthesiology, Ministry of Education; Key Laboratory of Anesthesiology of Zhejiang Province, Wenzhou Medical University; Wenzhou, Zhejiang 325027, China; Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China.
Department of Anesthesiology and Perioperative Medicine, the Second Affiliated Hospital and Yuying Children's Hospital; Key Laboratory of Pediatric Anesthesiology, Ministry of Education; Key Laboratory of Anesthesiology of Zhejiang Province, Wenzhou Medical University; Wenzhou, Zhejiang 325027, China; Key Laboratory of Structural Malformations in Children of Zhejiang Province and Key Laboratory of Environment and Male Reproductive Medicine of Wenzhou, Zhejiang 325000, China.
Cell Signal. 2023 Sep;109:110791. doi: 10.1016/j.cellsig.2023.110791. Epub 2023 Jul 3.
Curcumin has been shown to have anti-tumor proliferative properties, but its clinical application is limited by its low bioavailability, etc. Derivatives of curcumin have been developed and tested to improve its therapeutic efficacy. Derivative NL01 could induce ferroptosis through the HCAR1/MCT1 pathway.
CCK-8 was used to detect curcumin and derivative IC, crystalline violet staining was used to detect the proliferation inhibition effect of NL01 in ovarian cancer, western blot and qPCR were used to detect downstream related molecular expression changes, Transwell and survival curve assays were used to detect malignant phenotypic.
NL01 inhibited cell growth of Anglne and HO8910PM ovarian cancer cells by 13 times more potent than curcumin and induced ferroptosis of these two cells. we found that NL01 was able to reduce the expression of HCAR1/MCT1 and activate the AMPK signaling pathway, which in turn induced cellular ferroptosis via SREBP1 pathway. Knock-down HCAR1 expression revealed similar phenotype and pathway alterations to NL01 treatment. HCAR1 overexpression promoted a malignant phenotype and resistance to cisplatin in both cancer cells, whereas knockdown of HCAR1 showed the opposite phenotype. Subcutaneous transplantation tumor experiments in nude mice also showed that NL01 induced iron death and inhibited ovarian cancer proliferation. Further study showed that NL01 promoted the downregulation of GPX4 expression, which is related to ferroptosis, and that addition of ferrostatin-1 partially reversed NL01-mediated inhibition of the growth of two cell lines.
NL01 exhibits better anti-tumor growth properties than curcumin, and NL01 induces ferroptosis in ovarian cancer cells.
姜黄素已被证明具有抗肿瘤增殖特性,但其临床应用受到低生物利用度等限制。已开发并测试了姜黄素衍生物以提高其治疗效果。衍生物NL01可通过HCAR1/MCT1途径诱导铁死亡。
采用CCK-8检测姜黄素及衍生物IC,结晶紫染色检测NL01对卵巢癌的增殖抑制作用,蛋白质免疫印迹法和qPCR检测下游相关分子表达变化,Transwell实验和生存曲线分析检测恶性表型。
NL01抑制卵巢癌细胞系Anglne和HO8910PM细胞生长的能力比姜黄素强13倍,并诱导这两种细胞发生铁死亡。我们发现NL01能够降低HCAR1/MCT1的表达并激活AMPK信号通路,进而通过SREBP1途径诱导细胞铁死亡。敲低HCAR1表达显示出与NL01处理相似的表型和途径改变。HCAR1过表达促进两种癌细胞的恶性表型和顺铂耐药性,而敲低HCAR1则表现出相反的表型。裸鼠皮下移植瘤实验也表明NL01诱导铁死亡并抑制卵巢癌增殖。进一步研究表明,NL01促进了与铁死亡相关的GPX4表达下调,并且添加铁死亡抑制剂1可部分逆转NL01介导的对两种细胞系生长的抑制。
NL01比姜黄素表现出更好的抗肿瘤生长特性,且NL01可诱导卵巢癌细胞发生铁死亡。